Drug Trial Radar · NCT00963209
Tamoxifen Citrate in Patients With Breast Cancer
Last checked: Nov 19, 2026Latest source record: Aug 2, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
140
Planned (sponsor's estimate)
Start
Jun 2009
Primary completion
Sep 2013
Study completion Dec 2013
Sponsor
- Lead sponsor
- Centre Hospitalier Universitaire VaudoisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 21, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Estrogen can promote growth of endocrine sensitive breast cancer cells. Endocrine therapy with tamoxifen citrate may fight breast cancer by blocking the use of estrogen by the tumor cells. Pharmacokinetics and -genomics can have an impact on the efficacy of the treatment. PURPOSE: This phase III trial is studying blood samples to see if the level of active metabolites of tamoxifen can be improved in patients with breast cancer.
Conditions
- Breast Cancer
Interventions
tamoxifen citrateDrug
laboratory biomarker analysisOther
pharmacological studyOther
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determination of CYP2D6 genotype and determination of plasma concentrations of tamoxifen citrate and its metabolites (N-desmethyl-tamoxifen, 4-hydroxy-tamoxifen and endoxifen) under the 20 mg daily and 40 mg daily schedulesTime frame: Jan 2013
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hôpitaux Universitaire de Genève
Geneva, Switzerland · Recruiting
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.